Schiller P I, Messmer S L, Haefeli W E, Schlienger R G, Bircher A J
Department of Dermatology, University Hospital, Basel, Switzerland.
Allergy. 1997 Apr;52(4):432-5. doi: 10.1111/j.1398-9995.1997.tb01024.x.
Angioedema is a rare but potentially life-threatening adverse effect of angiotensin-converting enzyme inhibitors (ACEI) which usually occurs within the first weeks of therapy. We report three patients in whom ACEI-induced angioedema began with a late onset of 12-33 months, and who had an irregular, unpredictable course under ACEI therapy. In two patients, other drugs or trauma appeared to trigger some of the episodes. After withdrawal of the ACEI, the trigger drugs were well tolerated in provocation tests and upon re-exposure. To avoid putting some patients unnecessarily at risk for long periods, one should consider this irregular pattern of ACEI-induced angioedema and regularly monitor patients for this adverse effect.
血管性水肿是血管紧张素转换酶抑制剂（ACEI）罕见但可能危及生命的不良反应，通常发生在治疗的最初几周内。我们报告了3例患者，他们的ACEI诱导的血管性水肿起病较晚，为12 - 33个月，并且在ACEI治疗期间病程不规则、不可预测。在2例患者中，其他药物或外伤似乎引发了部分发作。停用ACEI后，激发试验和再次暴露时激发药物耐受性良好。为避免让一些患者长期不必要地处于风险中，应考虑ACEI诱导的血管性水肿这种不规则模式，并定期监测患者是否出现这种不良反应。
